Product Information
Registration Status: ActiveSIN09402P
BALAD TABLET 250mg is approved to be sold in Singapore with effective from 1997-02-07. It is marketed by ZIWELL MEDICAL (S) PTE LTD, with the registration number of SIN09402P.
This product contains Fusidic Acid 250mg in the form of ENTERIC-COATED TABLET. It is approved for ORAL use.
This product is manufactured by KOREAN DRUG CO LTD in KOREA, and in REPUBLIC OF.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.
Indication
For the treatment of bacterial infections.
Mechanism of Action
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.
Pharmacokinetics
- Absorption
- Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.
- Distribution
- Metabolism
- Metabolites include dicarboxylic ester/acid, 3-keto fusidic acid, hydroxy fusidic acid, glucuronide fusidic acid and a glycol metabolite.
- Elimination
Active Ingredient/Synonyms
Fucidate | Fucidin acid | Fusidate | Fusidic acid | Fusidine | Ramycin | Fusidic Acid |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.